SCHEMBL346471

SCHEMBL346471

CC(C)(C)OC(=O)NCCC1CCN(c2ccc(Br)cn2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 9/20 0.52
CKS1B P61024 2/20 0.51
SKP1 P63208 2/20 0.51
SKP2 Q13309 2/20 0.51
CPB2 Q96IY4 1/20 0.50
SIRT2 Q8IXJ6 1/20 0.50
SIRT1 Q96EB6 1/20 0.50
SIRT3 Q9NTG7 1/20 0.50
SUV39H2 Q9H5I1 2/20 0.47
ACACB O00763 2/20 0.43
ACACA Q13085 2/20 0.43
FGFR3 P22607 1/20 0.42
KDR P35968 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM5 P08912 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL345057 0.84 CHRM4 (0.57) CHRM4CHRM2CHRM5CHRM1CHRM3
SCHEMBL3269077 0.83 CHRM4 (0.49) CHRM4SIRT2SIRT1SIRT3CHRM2
SCHEMBL4417334 0.83 GPR119 (0.59) CHRM4CKS1BSKP1SKP2SIRT2
SCHEMBL24670864 0.82 PPARG (0.45) CHRM4CKS1BSKP1SKP2PPARG
SCHEMBL29990449 0.82 PPARG (0.45) CHRM4CKS1BSKP1SKP2PPARG
SCHEMBL3025692 0.82 CKS1B (0.60) CKS1BSKP1SKP2CPB2SUV39H2
SCHEMBL15258050 0.82 CKS1B (0.47) CHRM4CKS1BSKP1SKP2SIRT2
SCHEMBL30201637 0.79 CHRM4 (0.46) CHRM4CKS1BSKP1SKP2CPB2
SCHEMBL2404169 0.79 CHRM4 (0.45) CHRM4CPB2CHRM2CHRM1
SCHEMBL30201729 0.78 KMT2A (0.48) PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912218-B2 Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2014-12-16 US disclosed
US-8716289-B2 Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof SANOFI (FR) 2014-05-06 US disclosed
US-20120015950-A1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2012-01-19 US disclosed
US-20110212963-A1 ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212963-A1 ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF MET, ALK, REL CHRM4 1891/4885CKS1B 2188/4885SKP1 3476/4885
US-20120015950-A1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF INTS9, CDK8, SCN8A CHRM4 1210/4885CKS1B 1161/4885SKP1 4281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.